TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult female patient 18 years of age or older.~* Confirmed diagnosis of FIGO grade 2 endometrioid endometrial cancer on preoperative endometrial biopsy read by a pathologist with a subspecialty in gynecologic pathology.~* Stage 1 endometrioid endometrial cancer on preoperative endometrial biopsy.~* P53 wild type immunohistochemistry on preoperative endometrial biopsy.~* Patients eligible for primary staging surgery for definitive treatment for their cancer.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Required Initial Laboratory Values obtained within 3 days of enrolment following standard of care protocols: Absolute Neutrophil Count (ANC) ≥ 1,500/mm3; Platelet Count ≥ 100,000/mm3; eGFR ≥ 60 mL/min/1.73m2; Total Bilirubin ≤ 1.5 x upper limit of normal (ULN); AST / ALT ≤ 2.5 x upper limit of normal (ULN).~* Informed consent for this study is obtained and signed by the participant or have an acceptable Substitute Decision Maker (SDM) capable of signing the informed consent form on behalf of the participant.~Exclusion Criteria:~* Patients cannot be receiving systemic or hormonal therapy for treatment of the endometrial cancer.~* Prior radiation therapy for treatment of the endometrial cancer is not allowed.~* Stage 2 or 3 endometrioid endometrial cancer on preoperative endometrial biopsy.~* Abnormal p53 immunohistochemistry on preoperative endometrial biopsy.~* History of an allergic reaction to medroxyprogesterone acetate.~* History of venous thromboembolic event (including previous deep vein thrombosis or pulmonary embolism).~* Family history of venous thromboembolic event.~* Have a \>20 pack-year smoking history.~* Patients unwilling or unable to follow the study protocol schedule.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 - Megestrol (Type: EXPERIMENTAL): All study participants will receive Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \> 40 years;~* Women of childbearing potential must use two reliable contraceptive methods during the entire trial, from day 1 to one month after the end of the trial.~* Signing the study consent form;~* Stable cART since at least 3 months (ie no recent drug change);~* HIV-RNA below 100 copies for at least 6 months;~* HDL-cholesterol \<1.29 mmol/l for men; \<1.42 mmol/l for women~Exclusion Criteria:~* Pregnancy or lactation;~* Congestive Heart Failure;~* Malignant Hypertension;~* Acute or chronic coronary artery diseases;~* Any known cardiac arrhythmias;~* Diabetes;~* Concomitant cancer, rheumatologic disease or inflammatory bowel diseases;~* Concomitant renal or hepatic disease:~  * Creatinine above 150 micromol/L~ * Transaminases above 5 times upper normal limit~ * Prothrombin time (Quick) value below 50%;~* Prior intolerance to niacin therapy (reported in a medical report);~* Cyclosporine, anti-inflammatory drugs (other than aspirin) or cytokine therapy in concomitant intake;~* Abnormal thyroid function;~* Excessive consumption of alcohol;~* Known severe lactose intolerance.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ER Niacin/laropipant (Type: ACTIVE_COMPARATOR): ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
- ER Niacin/laropipant Placebo (Type: PLACEBO_COMPARATOR): ER niacin/laropiprant placebo p.m.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV adenocarcinoma of the pancreas that is unlikely to respond to existing therapy~* Measurable disease by MRI or CT scan~* Tumor must be at least 2 cm~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No active infection~* No nonmalignant systemic disease~* Not a high medical or psychiatric risk~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplastons~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Echinacea Angustifolia (AnxioCalm) in Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18 years of age (all races and ethnicity)~* Meet Diagnostic and Statistical Manual of Mental Disorders (DSM IV) any criteria for Generalized Anxiety Disorder (GAD from 5 to 9)~* mild to moderate symptom severity on the Beck Anxiety Inventory (BAI from 8 to 15)~* Hamilton Anxiety Rating Scale (HAM-A) score from 14 to 17~* Hospital Anxiety and Depression Scale (HADS-A) \[hospital anxiety and depression scale - anxiety subscale\] - 8-10~* Participants score 45-57 points of above on either the state or trait anxiety subscale of the State and Trait Anxiety Inventory of Speilberger (STAI)~* Able to understand and provide signed informed consent~* Able to participate in a 5-week study~Exclusion Criteria:~* Any diagnosed DSM-IV Axis II disorder~* Current DSM IV Axis I diagnosis of Major Depressive Disorder in the 6 month that precede the study. \[to exclude confounding psychiatric factors\]~* Danger of suicidality~* Treatment with Echinacea preparations in the 3 month that precede the study~* Psychotropic medication (especially anxiolytics) in the 3 month that precede the study~* Psychotherapy in the 3 month that precede the study~* Allergic reactions to plants of the Asteraceae family (Echinacea species, etc.)~* Treatment for AIDS or cancer~* Pregnant or lactating women~* Unstable medical condition (e.g., hypothyroidism, hypertension, myocardial infarction within 1 month, neoplastic condition)~* Alcohol or drug dependence within 3 months~* Allergy to Echinacea preparation~* Allergy to plants of the Asteraceae family (e.g., ragweed, asters, chrysanthemum)~* Allergy to mugwort, radioallergosorbent test (RAST), or birch tree pollen Concurrent tranquilizer, antidepressant or mood stabilizer therapy;~* Subjects receiving anti-anxiety medication (e.g., benzodiazepine, venlafaxine, buspirone, or SSRI)~* Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g., chamomile, St. John's Wort, Kava kava)~* Women of child-bearing potential not willing to employ a medically proven form of contraception (e.g., condoms, oral contraceptives, etc)~* Any other condition that precludes participation according to the judgement of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Echinacea angustifolia (Type: EXPERIMENTAL): 20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
- Placebo (Type: PLACEBO_COMPARATOR): Identical excipients as in the experimental arm, without the active ingredient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The (PIVOTAL) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 40 to 90 years of age~* Meet all indications for use as stated in the Medtronic Vascular AAA Endograft Instructions for Use~* Maximum aneurysm diameter of 4-5cm~* If female patient with child bearing potential, must have a documented negative pregnancy test within seven(7)days prior to inclusion~* Patient is willing and able to comply with the specified follow-up evaluation~* Life expectancy at least 3 years~Exclusion Criteria:~* Meet any of the Contraindications stated in the Medtronic Vascular AAA Endograft instructions for Use~* Known co-existing condition with a life expectancy of less than 3 years~* Major surgical or interventional procedure (vascular and/or non-vascular)within 30 days prior to study enrollment~* Subjects enrolled in another clinical trial or anticipated to be included into a trial, which may interfere with this study, or subjects already enrolled in this trial before.~* Planned conduit procedure for introduction of endograft

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Surveillance (Type: NO_INTERVENTION): None
- Early Endovascular Repair (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Operation for rectal cancer or ulcerative colitis an ileostomy (loop or end ileostomy within the last 7 days) OR~* ileostomy patient with contact to the stoma clinic OR~* Short bowel syndrome with a permanent ileostomy~* signed consent form~Exclusion Criteria:~* Complications associated with surgery~* Non-radical surgery~* Chemotherapy~* Poor compliance~* Other serious illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loperamide (Type: ACTIVE_COMPARATOR): Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
- Placebo (Type: PLACEBO_COMPARATOR): Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study for Evaluation of the Need for Protective Ileostomy After Low Anterior Resection Due to Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* radical resectable rectal cancer~* low sphincter-preserving resection of carcinomas of the lower and middle third~* preoperative normal continence~* preoperative normal sphincter function~* complete rings after stapler anastomosis~* impermeability of anastomosis for air~* written informed consent~Exclusion Criteria:~* reduced cooperation or drug abuse~* pregnancy~* psychosis~* age under 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is not taking systemic treatment~* The patient has not been treated with topical steroids for more than 15 days.~For the bullous pemphigoid group:~* clinical signs: erythematous-based lesions, especially on flexion areas of the arms and legs, not afflicting mucous membranes, and without atrophic scaring~* histology: without epidermal acantholysis~For the pemphigus group:~* patient with pemphigus~For the lupus group:~* systemic lupus patients: presence of the 4 diagnostic criteria for systemic lupus erythematosus as defined by the American College of Rheumatology (amended 1997)~* or characteristics of subacute cutaneous lupus: clinical, histological and immunological (anti-SSa)~* or clinical and histological characteristics of chronic lupus~For the control group:~* hospitalized patients with no history of auto-immune, inflammatory or evolving neoplastic disease~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant, parturient, or breastfeeding~For patients with bullous pemphigoid, pemphigus or lupus:~* The patient is taking systemic treatment~* The patient has been taking topical steroids for more than 15 days.~For the controls:~* autoimmune disease~* inflammatory disease~* evolving neoplastic disease~* surgery during the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bullous pemphigoid (Type: None): Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
- Other bullous-like auto-immune (Type: None): Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
- Control group (Type: None): Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Coronary artery disease after myocardial infarction with indication for CABG surgery~* Currently reduced global LVEF assessed at site by cardiac MRI at rest (25% ≤ LVEF ≤ 50%)~* Presence of a localized akinetic/hypokinetic/hypoperfused area of LV myocardium for defining the target area~* Informed consent of the patient~* 18 years ≤ Age \< 80 years~* Are not pregnant and do not plan to become pregnant during the study. Females with childbearing potential must provide a negative pregnancy test within 1-7 days before OP and must be using oral or injectable contraception (non-childbearing potential is defined as post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3 months before study start).~Exclusion Criteria:~* Emergency operation~* Presence of any moderate-severe valvular heart disease requiring concomitant valve replacement or reconstruction~* Medical History of recent resuscitation in combination with ventricular arrhythmia classified by LOWN ≥ class II~* Acute myocardial infarction within last 2 weeks~* Debilitating other disease: Degenerative neurologic disorders, psychiatric disease, terminal renal failure requiring dialysis, previous organ transplantation, active malignant neoplasia, or any other serious medical condition that, in the opinion of the Investigator is likely to alter the patient's course of recovery or the evaluation of the study medication's safety~* Impaired ability to comprehend the study information~* Absent informed written consent~* Treatment with any investigational drug within the previous 30 days~* Apparent infection (c-reactive protein \[CRP\] ≥ 20 mg/L, fever ≥ 38.5° C)~* Contraindication for MRI scan~* Immune compromise including active infection with Hepatitis B, C, HIV virus or seropositivity for Treponema pallidum~* Pregnant or breast feeding~* Childbearing potential with unreliable birth control methods~* Have previously been enrolled in this study, respectively phase I and phase II~* Known hypersensitivity or sensitization against murine products and human-anti-mouse-antibody-titer ≥ 1:1000~* Contraindication to bone marrow aspiration~* Known hypersensitivity against iron dextran

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- CD133+ autologous bone marrow stem cells (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Potential Effectiveness of a Case Management Intervention for Alcohol Use-Related Problems in Frequent Users of an Emergency Department: a Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 5 or more attendances during the previous 12 months at the Emergency Department of Hospital Clínic de Barcelona~* an AUDIT-C score higher than 5 points for men and 4 for women~* Patients who accept to participate in the study and give informed consent~* Exists valid contact information to reach patient in the future.~Exclusion Criteria:~* There is psychopathology that prevents study comprehension and/or future participation (i.e. cognitive impairment, acutely psychotic, acutely confused, intoxicated...)~* Patients who present medical conditions that predict that will not be able to participate in follow-up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intensive Case Management Intervention (Type: EXPERIMENTAL): Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of EndoClot™ Spraying After Endoscopic Resection of Large Colorectal Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a ≥20mm colon non-pedunculated polyp who are undergoing an ESD or EMR resection~* signed Informed Consent~Exclusion Criteria:~* Patients with known (biopsy proven) or strongly suspected invasive carcinoma in a potential study polyp~* Pedunculated polyps (as defined by Paris Classification type Ip or Isp)~* ulcerated depressed lesions (as defined by Paris Classification type III)~* polyposis syndromes~* inflammatory bowel disease~* emergency colonoscopy~* Poor general health (ASA (American Society of Anaesthesiologists) class\>3)~* Patients with coagulopathy with an elevated International Normalized Ratio (INR )≥1.5, or platelets \<50~* Poor bowel preparation~* pregnancy or breastfeeding~* Intervention planned using ORISE™ (Boston Medical) or LIFTUP™ (Ovesco) as lifting agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- EndoClot group (Type: ACTIVE_COMPARATOR): patients who are being provided with EndoClot adhesive spray after polyp resection
- Control group (Type: SHAM_COMPARATOR): no further prophylactic bleeding prevention after polyp resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues